Moderna to reveal late-breaking data on flu & RSV mRNA vax at ESCMID 2026
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Subscribe To Our Newsletter & Stay Updated